A typographical error was published in the review ‘Which antidepressants have demonstrated superior efficacy? A review of the evidence’ by (Montgomery et al. ) which appeared in 323–329 of International Clinical Psychopharmacology, Volume 22, issue 6.
The following declaration of research grants, equity and/or honoraria for lectures or for acting as consultants to pharmaceutical companies should have appeared in the conflict of interest statement in the acknowledgement section of the article.
Alan F. Schatzberg – Abbott, Corcept, Eli Lilly, Forest Labs, GlaxoSmithKline, Lundbeck, Merck, Neurocrine, Neuronetics, Novartis, Pathway Diagnostics, Pfizer, Quintiles, Somaxon, Somerset, Wyeth; named inventor on pharmacogenetic use patents on prediction of antidepressant response.
1. Montgomery SA, Baldwin DS, Blier P, Fineberg NA, Kasper S, Lader M, et al. 2007. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 22:323–329.